Epi Auto Injector denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for epi auto injector are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Your Epinephrine Auto-Injector: Not FDA-Approved

Epinephrine auto-injectors have FDA approval for emergency treatment of severe allergic reactions (anaphylaxis), so a "not FDA-approved" denial for this device-drug combination usually signals a specific issue: the plan may be questioning a particular brand, formulation, or concentration variation, or the denial may have been miscoded. This type of denial is appealable because the core active ingredient and the auto-injector delivery mechanism have long-established FDA approval.

## Why This Denial Is Appealable

FDA approval for epinephrine auto-injectors for anaphylaxis is well established. If BCBS is denying a specific brand or configuration, the appeal should clarify which FDA-approved product was prescribed and why it is medically necessary for your situation. A miscoded denial — where a clerical error triggered the wrong denial reason — can often be resolved at the first internal appeal level.

## Your Federal Appeal Rights

• Internal appeal: Under ACA Section 2719 and ERISA Section 503, you have the right to a full-and-fair internal review. Submit within the deadline stated in your denial letter (typically 180 days for non-grandfathered plans).
• External review: If the internal appeal is denied, you may escalate to an Independent Review Organization (IRO). The external review window is generally within approximately four months of exhausting internal remedies.
• Expedited review: If your condition is urgent or life-threatening, request expedited internal and external review — decisions are typically required within 72 hours.

## Documentation to Gather

• Diagnosis confirmation: Allergy or immunology records documenting a diagnosis of anaphylaxis risk or severe allergic reaction history.
• Prescriber letter: A detailed medical-necessity letter from your prescriber or allergist explaining why this specific FDA-approved epinephrine auto-injector is required and the clinical risk if access is delayed.
• FDA approval evidence: Print the FDA label for the exact product prescribed (available at DailyMed) and attach it to your appeal to rebut any claim of non-approval.
• Prior reaction history: Documentation of past anaphylactic episodes, emergency department visits, or allergist assessments.

## Criteria-Mapping Structure

Request BCBS's published medical policy for epinephrine auto-injectors. For each requirement listed, provide the corresponding chart documentation:

| Policy Requirement | Supporting Chart Evidence | |---|---| | Documented diagnosis qualifying for epinephrine auto-injector | Allergist/immunologist diagnosis note with date | | FDA-approved product prescribed | Prescriber's written order specifying exact FDA-approved brand/formulation | | Medical necessity narrative | Prescriber letter addressing clinical rationale |

Cross-reference the FDA-approved prescribing information for the specific product to confirm every approval criterion is met, and cite it directly in your appeal letter.